Peptides for Weight Loss: Market Trends, Brand Comparisons, and Efficacy Data Analysis
Abstract: The global peptide-based weight loss market, valued at $4.2B in 2023 (CAGR 12.8%), is dominated by GLP-1 agonists (semaglutide, tirzepatide). Brand comparisons reveal Novo Nordisk’s Wegovy leads efficacy (15% body weight loss) over generic peptide blends. Key technical advantages include high receptor specificity; disadvantages include high cost ($1,350/month) and cold-chain logistics (2-8°C). Regulatory compliance (FDA/EMA approval, GMP certification) is critical for supplier selection. Industry trends show a shift toward oral formulations and personalized peptide stacks.